PD-1_PD-L1通路、Th17和Tregs细胞在肿瘤免疫中的作用.pdf

（编校：蔺玥）3519.MODERNONCO31.No.182023年0 9 月现代肿瘤医学第31卷第18 期J Pharm,2019,554:72-80.58GU P,WUSIMAN A,WANG S,et al.Polyethylenimine coated PL-GA nanoparticles-encapsulated Angelica sinensis polysaccharideas an adjuvant to enhance immune responses J.CarbohydrPolym,2019,223:115128.59LUO L,ZHENG S,HUANG Y,et al.Preparation and characteriza-tion of Chinese yam polysaccharide PLGA nanoparticles and theirimmunological activity J.Int J Pharm,2016,511(1):140-150.60XU S,WUSIMAN A,LIU Z,et al.pH-responsive Astragalus pol-ysaccharides-loaded poly(lactic-co-glycolic acid)nanoparti-cles and their in vitro immunogenicity J.Int J Biol Macromol,2019,125:865-875.61ZHOU R,TENG L,ZHU Y,et al.Preparation of Amomum longil-igulare polysaccharides 1-PLGA nanoparticle and its immune en-hancement ability on RAW264.7 cells J.Int Immunopharma-col,2021,99:108053.62LI N,HU YL,HE CX,et al.Preparation,characterisation and anti-tumour activity of Ganoderma Lucidum polysaccharide nanopar-ticlesJ.J Pharm Pharmacol,2010,62(1):139.63宋志磊，潘玉涛，黄新河，等.可作为疫苗佐剂的云芝多糖磷酸钙纳米粒的制备与表征J.天然产物研究与开发,2 0 16,2 8(9):1357.SONG ZL,PAN YT,HUANG XH,et al.Preparation and charac-terization of polysaccharide krestin calcium phosphate(PSK-CAP)nanoparticle as a vaccine adjuvant J.Nat Prod Res Dev,2016,28(9):1357.64FAN YP,HU YL,WANG DY,et al.Effects of Astragalus polysac-charide liposome on lymphocyte proliferation in vitro and adjuvan-ticity in vivoJ.Carbohydr Polym,2011,88(1):68-74.65FAN Y,SONG X,GAO Y,et al.Preparation and optimization ofophiopogon polysaccharide liposome and its activity on KupffercellsJ.Int J Pharmaceut,2014,477(1-2):421-430.66LUO L,ZHENG S,HUANG Y,et al.Preparation and characteriza-tion of Chinese yam polysaccharide PLGA nanoparticles and theirimmunological activityJ.Int J Phann,2016,511(1):140.67GU P,XU S,ZHOU S,et al.Optimization of Angelica sinensispolysaccharide-loaded poly(lactic-co-glycolicacid)nanoparti-cles by RSM and its immunological activity in vitroJ.Int J BiolMacromol,2018,107(PtA):222-229.68MASUMI S,GEN T,TOKIO T,et al.Characterization of novel pa-clitaxel nanoparticles prepared by laser irradiation J.ChemPharm Bull(Tokyo),2022,70(4):269-276.69CHEN H,WEN J.Iron oxide nanoparticles loaded with paclitaxelinhibits glioblastoma by enhancing autophagy-dependent ferrop-tosis pathway J.Eur J Pharmacol,2022,921:174860.70ALAVI M,NOKHODCHI A.Micro-and nanoformulations of pa-clitaxel based on micelles,liposomes,cubosomes,and lipid nanop-articles:Recent advances and challenges J.Drug Discov Today,2022,27(2):576 584.71SCHMIDT KT,KARZAI F,BILUSIC M,et al.A single-armphase II study combining NLG207,a nanoparticle camptothecin,with enzalutamide in advanced metastatic castration-resistantprostate cancer post-enzalutamide J.Oncologist,2022,27(9):718-e694.PD-1/PD-L1通路、Th17和 Tregs 细胞在肿瘤免疫中的作用张蓝方，张明娟，许进秀，李珊，陈玉，王文静，杨君田，李升云，谷美玲山东大学附属威海市立医院肿瘤医学中心，山东威海2 6 42 0 0【指示性摘要】近十年，以PD-1/PD-L1阻断剂为代表的针对免疫检查点的免疫治疗已经成为许多恶性肿瘤治疗模式的重要组成部分，免疫检查点抑制剂被证明可以使肿瘤患者的失能T细胞恢复活力，从而使肿瘤获得较长的缓解。在取得较好的疗效同时,PD-1/PD-L1免疫治疗在实体恶性肿瘤中的阻断效果仍存在不足,这可能与复杂的肿瘤微环境有关。作为肿瘤微环境中重要的免疫细胞,Tregs和Th17细胞被证明参与了肿瘤的发展。目前,PD-1/PD-L1通路、Tregs与Th17细胞之间的复杂关系尚未完全阐明。本文就PD-1/PD-L1通路、Tregs与Th17细胞的相互作用机制进行综述,以期为今后的肿瘤治疗提供新的思路。【关键词】肿瘤;PD-1/PD-L1;Th17;Tregs【中图分类号】R730.51【文献标识码】AD0I:10.3969/j.issn.1672-4992.2023.18.035【文章编号】16 7 2 4992-（2 0 2 318-3519-0 5【收稿日期】2020-09-16【修回日期】20230414【作者简介】张蓝方（198 4一），女，山东威海人，主治医师，博士，主要从事肿瘤内科临床研究。E-mail:【通信作者】张明娟（197 0），女，山东威海人，主任医师，主要从事肿瘤内科临床研究。E-mail:3520PD-1/PD-L1通路、Th17和 Tregs 细胞在肿瘤免疫中的作用张蓝方，等Role of PD-1/PD-L1 pathway,Th17 and Tregs cells in tumor immunityZHANG Lanfang,ZHANG Mingjuan,XU Jinxiu,LI Shan,CHEN Yu,WANG Wenjing,YANG Juntian,LI Shengyun,GU MeilingCancer Medical Center,Weihai Municipal Hospital,Shandong University,Shandong Weihai 264200,China.AbstractTumor immunotherapy,especially PD-1/PD-L1 immunosuppressive checkpoint inhibitors,has becomean important part of tumor treatment strategy in the past decade.The blocking of PD-1/PD-L1 signaling pathwayrelieves the inhibition of PD-1 pathway on T cells,promotes the attack of activated T cells on tumor cells,and hasadvantages in prolonging the remission period of tumor.PD-1/PD-L1 immunotherapy is effective in the treatment ofsolid malignant tumor,but it also has some shortcomings,which is related to the complexity of tumor microenviron-ment.Tregs and Th17 cells play an important role in tumor microenvironment and are closely related to the occurrenceand development of tumors.However,the complicated relationship between PD-1/PD-L1 pathway,Tregs,and Th17cells has not been fully clarified.Here,we summarized the immunoregulation mechanisms and discussed the crosstalkin PD-1/PD-L1 pathway,Tregs and Th17 cells,hoping to provide novel insights for the future cancer treatment.Key words tumor,PD-1/PD-L1,Th17,TregsModern Oncology 2023,31(18):3519-3523单克隆抗体（mAb）的免疫检查点抑制剂（ICI）的出现，尤其是程序性细胞死亡1(PD-1)/PD-1配体(PD-L1)阻断剂,极大地改变了多种晚期恶性肿瘤的治疗前景。与化疗和靶向治疗不同，免疫检查点阻断剂着手于重新规划肿瘤免疫反应,在肿瘤患者治疗后的长期获益方面具有优势。虽然与放化疗或其他靶向治疗药物相比，它们的副作用被认为是可控的,且耐受性良好,但在临床疗效上看,ICI对实体恶性肿瘤的阻断效果仍存在不足,单药治疗的